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Abstract
The Lung Clearance Index (LCI) is an index derived from washout recordings, able to detect early peripheral airway
damage in subjects with cystic fibrosis (CF) with a greater sensitivity than spirometry.
LCI is a marker of overall lung ventilation inhomogeneity; in fact, as pulmonary ventilation worsens, the number of
tidal breaths and the expiratory volumes required to clear the lungs of a marker gas are increased, as documented
by a greater value.
In the field of CF, LCI allows indirect investigation of the small airways (< 2 mm) the site where, from a
pathophysiologic point of view, the disease begins due to the defect of the CF transmembrane-conductance
regulator (CFTR) protein. Infant pulmonary function changes seem to occur before clinically overt symptoms of
lower respiratory illness occur.
When performing the test, it is important to refer to the American Thoracic Society and European Respiratory
Society consensus statements and apply a strict standardization.
In Italy the first tests were carried out in 2014 for research purpose and now approximately 10 centers are
collecting data and are experiencing a consistency in repeating exams.
Currently in Italian centers children at pre-school age are the main target: in this population it is important to have
a sensitive and feasible test, non-invasive, that can be performed at tidal volume without sedation, and requiring
minimal cooperation and coordination, and that can be used longitudinally over time. Another target could be the
transplanted subjects to detect early signs of lung function decline.
The content of this paper captures the experience and discussions among some of the Italian centers where LCI is
currently used for research and/or in clinical practice about the method and the need to have a common
approach.
The aim of this paper is not to describe the methodology of MBW, but to inform the pediatric community about
the possible application of LCI in CF.
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Introduction
The multiple breath washout test (MBW) has been used
for long time to measure static lung volumes during
tidal breathing, with minimal cooperation and coordin-
ation needs. Recently the lung clearance index (LCI), an
index derived from washout recordings, has proven to
be able to detect early peripheral damages in subjects
with cystic fibrosis (CF) with a greater sensitivity than
conventional spirometry. This is a potential big oppor-
tunity for research and ultimately for clinical use.
The content of this paper captures the experience and
discussions about the method and the need to have a
common approach among some of the main Italian cen-
ters where LCI is currently used for research and/or in
clinical practice.
The aim of this paper is not to describe the method-
ology of MBW, but to inform the pediatric community
about the possible applications of LCI in CF, while many
papers about the standardization are currently available
in the literature.
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Lung clearance index: state of the art
The measurement of lung volume using inert gas dilu-
tion was reported first in the 1940s [1, 2]. The first re-
spiratory mass spectrometer device was developed in
1952 [3] but the modern era of respiratory gas chroma-
tography began in 1971 [4]. Initially MBW devices used
4% sulfur hexafluoride (SF6) as inert gas, but at present
this concentration of the gas is generally no longer uti-
lized, mostly because of concerns regarding greenhouse
gas emissions and costs. Nitrogen wash-out devices
measuring gas concentration via molar mass have been
used since 1985 [5, 6]. For main stream molar mass inert
gas concentration calculation, temperature and humidity
corrections are necessary [7]. Different devices show
similar performance in terms of discrimination power
and reproducibility, but they cannot be considered as
interchangeable [8]. Current data have not indicated any
ethnic differences [9].
MBW devices measure how many lung volume turn-
overs (usually 6–7) are needed to wash out traces of an
inert gas from the lungs. In the case of exogenous inert
gases (SF6, He), the gas is released at a known concen-
tration during the wash-in phase and the wash-in is
complete when the expired gas concentration reaches
the concentration of the gas supplied. On the contrary,
no formal wash-in phase is required for nitrogen and
few tidal breaths are carried out to ensure that the
concentration of N2 is stable (normally 80%); during the
washout phase, the subjects inhale gases that do not
contain the tracer gas (room air for SF6 devices and
100% oxygen for N2 devices). The washout is interrupted
once the tracer gas concentration reaches 1/40th of its
starting concentration in 3 consecutive breaths [10, 11].
LCI is a marker of overall lung ventilation inhomogen-
eity; in fact, as pulmonary ventilation worsens, the num-
ber of tidal breaths and the expiratory volumes required
to clear the lungs of the marker gas are increased, as
documented by a greater LCI value [12].
Over the past 15 years, the application of LCI in CF
has become widespread. In the field of CF, LCI allows
indirect investigation of the small airways (< 2 mm); the
site where, from a pathophysiologic point of view, the
disease begins.
Cystic fibrosis
Unlike the conducting airways, where mucosal biofilm is
removed by ciliary movements, in the smaller airways the
liquid must be reabsorbed, otherwise the exchange is
hindered. The defect of CFTR (cystic fibrosis
transmembrane-conductance regulator) protein explains
the damage at the early stage of cystic fibrosis disease: the
protein is expressed in the airway surface epithelium, that
loses its absorption capacity, and in the subcutaneous
glands, that secrete an altered mucus obstructing the
glandular ducts [13, 14]. In addition, the pH of the mem-
brane is affected by the impaired exchange of chloride and
bicarbonate with serious consequences on innate immunity
[13].
CF leads to obstructive clinical presentations, with ven-
tilation inhomogeneity (VI), heterogeneous flow-volume
loops and uneven topographic damage distribution [15].
Lung disease remains the main cause of morbidity and
mortality in patients with CF therefore it would be
crucial to assess early intervention strategies, before
clinical symptoms become apparent, through suitable
and sensitive tools.
Several instrumental approaches are available today to
detect lung damage in the early stages of the disease.
Examination of broncho-alveolar lavage (BAL) in
children under 2 years of age may detect positivity for
Staphylococcus aureus, Pseudomonas aeruginosa as well
as neutrophils and elastase positivity, thus testifying that
infection and inflammation begin early [16]. Detected at
3 months of age, elastase positivity in BAL proved to be
an air trapping and bronchiectasis risk indicator as
confirmed by CT and MRI in the following 3 years [16].
Even forced (thoracic and abdominal) FEVs may detect
early signs of the disease [17]. Further diagnostic tools
include electrical impedance tomography [18] and
Helium MRI [19], an index of inhomogeneous perfusion
[20–22], which may provide further information as com-
pared to MBW, where non-ventilated regions do not
contribute to the inhomogeneity shown by MBW [23].
Infant pulmonary function changes seem to occur
before clinically overt symptoms of lower respiratory
illness occur [24]; in fact, structural changes in small
airways start shortly after birth in CF, they accumulate
over time and subsequently reach a certain functional
threshold quantifiable using MBW. LCI has proved able
to detect early lung injury in CF in a large longitudinal
study [25]. Moreover, LCI showed to be indicative for
the presence or absence of structural lung changes after
3 years in 87% of cases in a prospective, longitudinal
study [26].
Spirometry is conventionally used in the assessment of
CF lung disease, however FEV1 can remain within normal
limits throughout childhood. LCI requires only passive
co-operation and it is able to identify inhomogeneous ven-
tilation in children with normal spirometry [27]; moreover,
it is much more sensitive but less specific than FEV1 [28].
LCI discriminates infants with CF versus healthy subjects
and it gains more sensitivity if it is considered together
with FEV1 [29]. Abnormal LCI values in the preschool age
range are stronger predictors than preschool FEV1 of
subsequent abnormal school age FEV1 [30]. LCI can be
considered as a test performed at rest that predicts some
abnormalities appearing at exercise in CF children with
normal spirometry as well [31].
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Furthermore, baseline LCI allows predicting pulmon-
ary exacerbations in young patients with CF with the in-
crease of 1 z-score resulting in 12% increase in the
number of exacerbations/year and correlates with the re-
spiratory domain score at the CFQ-R (cystic fibrosis
questionnaire-revised), a validated patient-reported out-
come, even in the subgroup with normal FEV1 [32].
According to the experiences collected so far, LCI po-
sitioning is in mild pulmonary disease, for early changes
detection and possibly for disease evolution monitoring,
considering that the examination must be performed on
lungs that are still functioning.
LCI within-subject variability is low and this
strengthens the use of LCI to monitor lung disease pro-
gression in CF patients. An increase in LCI > 17% com-
pared to previous LCI-measurement in clinically stable
CF patients may therefore indicate early lung disease
progression [33].
Furthermore, in the small group of patients with clin-
ical and CT evidence of lung damage only in late adoles-
cence or adult age, LCI may play a role as well: in
particular when the result of FEV1 is within the lower
limit of normal (LLN) [34] and/or there are no reduc-
tions of FEF25 (forced expiratory flow at 25% of FVC). It
can be clearly stated that LCI cannot be used alone as
an index of the severity of disease and doesn’t give any
further information in grading the severity of obstruc-
tion. At this aim, conventional spirometry, in particular
FEV1 should be considered as the reference.
Sensitive outcome measures to assess the efficacy of
therapeutic interventions in patients with CF play a great
role. LCI, but not spirometry was able to detect a treat-
ment effect from hypertonic saline inhalation in patients
with CF with mild disease [35]. Moreover, LCI is an indi-
cator of improvement after intra venous antibiotic treat-
ment and the higher the LCI value is at the beginning of
the study the more it decreases after treatment [36].
LCI has proven to be a more effective and sensitive al-
ternative than FEV1 to assess response to treatment with
Ivacaftor in patients with CF who have the
G551D-CFTR mutation and reduced lung function, but
still normal spirometry [37]. Using z-scores to adjust for
the known growth (i.e. height)-related decline in LCI
during early childhood [38] increases the validity of re-
sults in evaluating treatment effects [24].
LCI has been also suggested as a surrogate for chest com-
puted tomography to detect structural lung abnormalities
in preschool and school age children with CF, however it
cannot replace chest imaging using computed tomography
to screen for bronchiectasis in this population [39].
A systematic review of the clinimetric properties of
LCI demonstrates its reliability, validity and responsive-
ness coupled to an attractive feasibility profile [40].
Eventually LCI can be used for research purposes
because smaller sample sizes are required compared to
FEV1, which requires large samplings and long observa-
tion periods [41].
Technical aspects in pediatric patients with CF
In recent years, the statements and guidelines of the
international scientific societies about the use of tests
like LCI have increased [10, 11, 42, 43].
Several MBW devices for LCI measure in children and
adults [44] have been compared, but a deep analysis of
different devices goes beyond the purpose of this paper.
Exhalyzer® D is the device chosen by the European
Cystic Fibrosis Society [8] and the one most frequently
used in Italy. However, several software are available for
analyses of MBW indices [45].
Hereinafter we are not going to describe in depth the
technical aspects of MBW; for this purpose, it is import-
ant to refer to the American Thoracic Society and Euro-
pean Respiratory Society consensus statements when
performing the test, for preschool age patients, a specific
document has recently been published [43], for children
and adults the 2013 guidelines should be followed [11].
The preschool subject should be tested in seated pos-
ition breathing at a tidal volume through a mouthpiece
or a mask closely adhering to the face (Fig.1). The tracer
gas (helium, argon, or sulfur hexafluoride) is first washed
in then washed out; alternatively, 100% oxygen can be
inhaled to wash out the resident nitrogen from the
lungs, without a wash-in phase.
There are many variables that need to be taken into
account when performing the test:
 the stability of clinical condition
 the administration of bronchodilator therapy
Fig. 1 Measurement conditions. Preschool girl performing MBW
while seating and breathing at tidal volume through the
mouthpiece and a bacterial filter (permission to
publication obtained)
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 the possible execution of physiotherapy before
examination, that can modify airway obstruction and
ventilation inhomogeneity
 equipment calibration (depending on temperature,
etc.)
 the stability of the wall mounted gas-system
In order to standardize all technical variables, it would
be desirable to use the standard kit and all other mate-
rials provided by the manufacturer.
Criteria for technical acceptability are reported in the
ERS/ATS Consensus [11] but there are several aspects
that require adaptation to the preschool age [46]. The
environment for preschool MBW testing should be as
child-friendly as possible and distraction during the
assessment must be enough to take the child’s attention
away from his/her breathing. LCI success rates are 76–
90% in infants during quiet natural sleep [47, 48] or with
sedation [49].
In preschoolers, the use of a facemask, sealed with
putty, and video distraction, achieves success rates of
nearly 80%, though varying with age: 50% in 2–3 years
old rising to 87% of 5–6 years old [50]. Similarly, LCI
variability improves with age to a within-test CV (coeffi-
cient of variation) of 5.2% in preschoolers [50]. In a clin-
ical study, it was possible to perform LCI examination in
90% of cases in the 4–16 age group, while 2 or more
measurements were performed in 41% of cases [51].
According to the ERS/ATS consensus statement [43] at
least three acceptable MBW trials whenever possible
should be collected, however, in pre-school children data
reported from only two acceptable trials provide compar-
able outcomes, ability to discriminate between health and
disease, and associations with clinical markers of CF lung
disease, improving feasibility in young children participat-
ing in longitudinal assessments and clinical trials [52].
LCI also requires some time to be performed, because
repeated measurements may take several times to ensure
reliable results. The reported average duration of a
N2-MBW test in children with cystic fibrosis is 3.3 min
(1.2 to 6.4), while it is 2.9 min (1.2–4.0) in controls [51].
The cross-contamination between patients can be
minimized by cleaning and using disposable inserts [53]
and following specific CF guidelines on infection preven-
tion and control [54].LCI tests with different end-points
(e.g. 1/30th, 1/20th or 1/10th of the initial concentration
of tracer gas, or using a fixed washout period, for
example 20s, or a fixed number of breaths) have been
studied to save time in performing the test [55].
Reference values depend on the age of subjects, the type
of device available, and the type of software used. Depend-
ing on the choice of gas, MBW indices differ substantially
[44], for example, because helium is much lighter than
Sulphur hexafluoride it generates higher LCI values [11].
Considering the age of subjects and factors such as gas,
equipment, dead space, software, LCI is usually below 8.5
lung turnovers in healthy subjects [45]. Other relevant fac-
tors influencing MBW measures, are the posture during
tests (supine or seated) [56], as well as sedation.
Reference values are not interchangeable [40] and few
data for MBW measurements across different age groups
are available [57].
LCI is thought to be independent of age, but recent
evidences suggest that in the first 5 years of life LCI
decreases in a nonlinear pattern as height increases;
therefore, the use of fixed upper limit of normal (ULN)
is not appropriate for children < 6 yr. [38].
The different algorithms used in the available software
package to calculate LCI values could explain some false
normal values in CF patients, highlighting the need for
meticulous standardization not only of procedures but
also of software algorithms [58].
The Italian scenario
Eight centers are currently using LCI in Italy. The first
tests were carried out in 2014 for research purpose and
now some centers are collecting data and are experien-
cing a consistency in repeating exams, provided that
they apply a strict standardization.
Indications
Pulmonary function tests play a key role in the manage-
ment of CF in Italian centers, in children over 6 years of
age. However, several matters hinder the same efficacy
in the assessment of younger children and infants.
LCI looks as an attractive opportunity, because it is a
sensitive, non-invasive and feasible test, particularly in
the preschool age target when minimal cooperation and
coordination are required during the test at tidal
volume.
Currently, there is no sufficient evidence to recom-
mend inclusion of LCI into the routine diagnostic evalu-
ation and clinical monitoring of patients with CF, as
stated by the Cystic Fibrosis Foundation in 2015 [42],
but LCI may be considered as a tool to evaluate ongoing
symptoms or monitor response to treatment, and as a
measure in clinical research studies [41].
The primary use of LCI is to study CF patients of all
ages without clinical or functional evidence of lung
impairment to evaluate whether subtle lung disease is
present. Currently the main target of LCI in Italian
centers are children of preschool age. Children under 6
years of age have a developing respiratory system and a
constantly evolving respiratory physiology, they experi-
ence frequent clinical episodes that may result in severe
damage. Within this age group a particular subgroup is
represented by children aged 2 to 6 years: they are too
old to be sedated, but too young to actively cooperate
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[10]. In this age group spirometric parameters such as
mid-expiratory flows (FEF25, FEF50 or FEF75) are not re-
liable. Therefore, it is important in the preschool group
to have a sensitive test, to be performed without sed-
ation, at tidal volume, and to be used longitudinally over
time. Although it is a non-invasive test, LCI can be
time-consuming and requires dedicated staff, therefore
the recommended frequency should be every 6months
under clinical stable conditions.
Furthermore, in transplanted subjects it is crucial to
detect early signs of lung function decline and LCI, per-
formed at an increased frequency, can be used for early
medical referral.
In these scopes of LCI, preschool children and trans-
planted subjects, a prospective data collection is needed
to acquire a greater experience in measurement and
maximize the advantages.
Interpretation of results
The LCI results are clearly influenced by biological vari-
ability and should be interpreted within the clinical his-
tory of the patient, taking into account many
physiological variables and technical issues. Up to now,
LCI calculated as 1/40th of starting end-tidal concentra-
tion of N2 (LCI 2.5%) is the most robust output of the
N2-MBW test; the validity of its shortened version, i.e.
LCI 5%, that is 1/20th of starting end-tidal concentration
of N2, has not reached a consensus yet.
Table 1 shows three different N2-MBW reports, as
available with Exhalyzer® D. The means and coefficient
of variation (CV%) of three test results are displayed.
Subjects A and B completed three reproducible runs,
defined as a variation of FRC and LCI 2.5 values within
10%. Subject C performed a poor technically acceptable
test, with an FRC CV% above 15% and therefore results
were not considered valid.
The first subject (A) is a 32 year-old man with CF,
without pancreatic insufficiency and with normal
pulmonary function (FEV1 equals to 95.1% predicted);
LCI was 7.15 thus confirming an optimal respiratory
functionality. Subject B is a boy with CF aged 5 years
old, with an impaired pancreatic function. Classical spir-
ometry was not available due to the young age, and
therefore LCI was used as a mean of respiratory surveil-
lance. Unfortunately, LCI was above the considered nor-
mality cut-off, describing an early lung disease otherwise
not detectable. This information forced the CF team to
further investigations. No conclusions could be drawn
for subject C.
The understanding of other alternatives to LCI as out-
comes of the N2-MBW test, such as the phase III ana-
lysis of the expirogram, i.e. Scond and Sacin, or moment
ratios, i.e. M1/M0 or M2/M0, is beyond the scope of this
report.
Interpretation and management of LCI results differ
among centers. In order to manage the informative con-
tent of LCI tests, it might be useful to measure other
parameters together with LCI, such as those coming
from spirometry, when available, or from lung imaging,
integrating the results from a clinical point of view,
keeping in mind that different parameters are measuring
different elements: some structural, some functional.
Table 1 Standard N2-Multiple Breath Washout reporting available in Italian CF centers
CV = coefficient of variation; functional residual capacity; LCI 2.5% norm = normalized lung clearance Index at 2.5%; LCI 5% norm = normalized lung clearance
index at 5%; M1/M0 = moment ratio: non-uniform alveolar flow volume distribution; M2/M0 = moment ratio: lung regions that empty late during the washout;
Scond*VT = convection-dependent inhomogeneity corrected for tidal volume; Sacin*VT = diffusion-convection-dependent inhomogeneity corrected for tidal
volume; RQ= respiratory quotient; VT = tidal volume; VdCO2 = volume of gas coming from dead space; CEV = cumulative expired volume
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MRI indices strongly correlated with LCI, as well as
FEV1 [59]; on the other hand, LCI, but not body plethys-
mography, is associated with air trapping detected by
CT scan [60].
LCI has been reported to be a useful marker to
track early disease progression and based on the re-
sults of LCI more accurate decisions as the indication
of other diagnostic tests, their early execution vs rou-
tine planned management and, last but not least, it
may serve as a tool to guide therapies in young pa-
tients with CF [61, 62].
It should be highlighted that a good part of literature
data has been obtained with SF6 and mass spectrometry,
expensive equipment used in a few laboratories; there-
fore, there is the unmet need for new data to be ac-
quired with the recently introduced instruments in
children.
Health care professionals involved in LCI measure-
ments are aware that a gold standard is unavailable, dif-
ferent methods have different reference values, different
specificity and sensibility. In the Italian centers the limits
of the exam are well-known, and so is the demand for
working together in order to finalize a common
behavior.
Recent studies have advanced our understanding of
the role of the LCI in clinical practice: LCI is a promis-
ing surveillance tool to monitor early structural CF lung
disease in preschool and school-age children although
its exact clinical utility is still uncertain [63].
Conclusions
LCI can bring added value to the evaluation of the
patient’s clinical status. It is difficult to quantify this
extra-informative content as it is extremely variable
depending on the characteristics of each patient. It
can be affirmed that the exam should be performed
in the right patient to obtain meaningful data and to
demonstrate its full value. Furthermore, LCI results
should always be considered in the framework of
symptoms, signs and other clinical exams to monitor
disease severity over time and evaluate response to
treatment.
In the preschool children group MBW test appears to
provide the greatest discrimination, among the available
lung functional tests, between children with CF and
healthy control subjects, due to the regionally heteroge-
neous nature of early airway obstruction.
In Italy, time is probably ripe to create a specific LCI
working group focusing on developing collaborative
projects. A priority should be the implementation of a
common data collection tool to minimize the differ-
ences among centers and obtain comparable tests.
Device-specific reference values for preschool Italian
children are also urgently needed.
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